FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to a pharmaceutical composition for inhibiting expression of complement component C5, containing a lipid complex, where the lipid complex includes double-stranded ribonucleic acid, and the pH of the solution of the lipid complex is 2.0 or more and 5.0 or less, or 7.5 or more and 11.0 or less. Also disclosed is a method of producing a pharmaceutical composition and a method of stabilizing it. Invention also relates to a method of treating paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
EFFECT: invention provides effective suppression of expression of complement component C5.
23 cl, 6 dwg, 31 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DOUBLE-STRANDED RIBONUCLEIC ACID INHIBITING EXPRESSION OF C5 COMPLEMENT COMPONENT | 2019 |
|
RU2781954C1 |
| MIR-29 MIMETICS AND WAYS OF USE THEREOF | 2015 |
|
RU2712511C2 |
| SIRNA AND THEIR USE IN METHODS AND COMPOSITIONS FOR INHIBITING NRARP GENE EXPRESSION | 2016 |
|
RU2738971C2 |
| NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, METHOD OF PRODUCTION AND USE | 2020 |
|
RU2828679C2 |
| MIRNA STRUCTURES WITH HIGH ACTIVITY AND REDUCED EXPOSURE OUTSIDE THE TARGET | 2016 |
|
RU2788030C2 |
| RNA INTERFERENCE-MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION WITH THE USE OF A SMALL INTERFERING NUCLEIC ACID (siNA) | 2011 |
|
RU2745848C2 |
| COMPOSITIONS BASED ON iRNA SERPINA1 AND THEIR APPLICATION METHODS | 2017 |
|
RU2761667C2 |
| NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE, METHOD OF PRODUCTION AND USE | 2020 |
|
RU2816898C2 |
| COMPOSITIONS AND METHODS FOR INHIBITION OF PROTEOLYTIC PATH OF ARGININE/N-DEGRON | 2020 |
|
RU2787841C2 |
| DOUBLE-CHAINED OLIGONUCLEOTIDE SPECIFIC TO CTGF GENE AND COMPOSITION CONTAINING IT FOR PREVENTION AND TREATMENT OF FIBROUS DISEASES AND DISEASES ASSOCIATED WITH RESPIRATORY SYSTEM | 2020 |
|
RU2807108C1 |
